Page last updated: 2024-11-08

lotaustralin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

lotaustralin: higher homologue of linamarin from flax; a cyanogenic glycoside; RN given refers to (R)-isomer; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID441467
CHEBI ID6542
SCHEMBL ID42924
MeSH IDM0041788

Synonyms (25)

Synonym
2(r)-hydroxy-2-methylbutyronitrile-beta-d-glucopyranoside
p588137a94 ,
butanenitrile, 2-(beta-d-glucopyranosyloxy)-2-methyl-, (r)-
unii-p588137a94
534-67-8
C08334 ,
lotaustralin
2-hydroxy-2-methylbutyronitrile-beta-d-glucopyranoside
AC1L9B81 ,
(2r)-2-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybutanenitrile
2-methyl-2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybutanenitrile
butanenitrile, 2-(.beta.-d-glucopyranosyloxy)-2-methyl-, (2r)-
.beta.-d-glucopyranosyloxy-2-methylbutyronitrile (r)
SCHEMBL42924
CHEBI:6542
surecn42924
zinc04097529
(2r)-2-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-butanenitrile
DTXSID30897501
Q905492
(r)-2-methyl-2-(((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)butanenitrile
(r)-2-(beta-d-glucopyranosyloxy)-2-methylbutyronitrile
(2r)-2-(beta-d-glucopyranosyloxy)-2-methyl-butanenitrile;
(2r)-2-methyl-2-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}butanenitrile
AKOS040752682

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"The toxic effects of cassava diets on humans were reviewed."( The toxic effects of cassava (manihot esculenta grantz) diets on humans: a review.
Agunbiade, OO; Aregheore, EM, 1991
)
0.28
" In order to achieve safe levels of 10 μg/g in cassava products, new methods of processing, especially for cassava containing more than 250 μg CN eq."( Strategies for elimination of cyanogens from cassava for reducing toxicity and improving food safety.
Nambisan, B, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
cyanogenic glycosideA glycoside in which the aglycone contains a cyanide group. A cyanogenic glycoside can release poisonous hydrogen cyanide if acted upon by some enzyme.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (4)

PathwayProteinsCompounds
lotaustralin degradation18
neolinustatin bioactivation08
lotaustralin biosynthesis014
superpathway of linamarin and lotaustralin biosynthesis023

Research

Studies (31)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (22.58)18.7374
1990's5 (16.13)18.2507
2000's7 (22.58)29.6817
2010's12 (38.71)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.82

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.82 (24.57)
Research Supply Index3.50 (2.92)
Research Growth Index4.65 (4.65)
Search Engine Demand Index39.34 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.82)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (6.25%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other30 (93.75%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]